MyFinsight
Home
Blog
About
Back
Income Statement
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
source: myfinsight.com
Net loss
attributable to common...
-$982,566
(45.85%↑ Y/Y)
Net loss
attributable to...
-$6,150
(83.67%↑ Y/Y)
Net loss
-$988,716
(46.62%↑ Y/Y)
Total operating loss
-$938,678
(47.87%↑ Y/Y)
Total other expense,
net
-$50,038
Research and development
credit
$281
Total operating
expenses
$938,678
(-49.48%↓ Y/Y)
Interest expense
$50,319
(197.99%↑ Y/Y)
General and
administrative
$807,548
(-18.50%↓ Y/Y)
Research and development
$131,130
(-84.88%↓ Y/Y)
Back